As the figure shows, the SLC2A10 expression level correlates with poorer prognosis and high immune infiltrates in colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), lower grade glioma (LGG) and rectum adenocarcinoma (READ) (Fig. 5A, C, E, I). This evidence concerns the gene SLC2A10 and central nervous system cancer.